A great day with beautiful weather this year! The family of Bennett Clayton DeBlieck extends their sincere appreciation to the many people who have made this event a success. We thank the golfers, sponsors, donors and volunteers. Shoreland staff, friends and families who of contributed in many ways. Because of your generosity, The Bennett Clayton Foundation continues to meet and surpass its expectations.
The winners of this year's tournament are
1st Place with a score of 54 - Jeri Meola, Chris Madrano, Aaron Nelson, Barb Moxneas
2nd Place - Owen Bernsdorf, Danny Gill, Andy Carroll, Zach Frank
3rd Place - Mike Mattuiz, Arthur Hartmann, Brain Braun, Paul Amos
Osteogenesis Imperfecta (OI) is a genetic bone disorder characterized by fragile bones that break easily. It is also known as “brittle bone disease”. (See OIF.org website for more information.)
Established in 2003, The Bennett Clayton Foundation for Children with OI works to benefit all children with Osteogenesis Imperfecta. The DeBlieck Family organized BCF in honor of Bennett after he was diagnosed with OI at the age of one.
Financial support by generous individuals and corporations enables the foundation to provide support to OI families in the form of personal health grants, college scholarships, social and educational gatherings, research funding and financial assistance for conference attendees.
The Bennett Clayton Foundation recognizes the importance of research into the cause, treatment and possible cure for Osteogenesis Imperfecta. When we become aware of studies related to OI, we attempt to share that information with BCF friends.
Although the foundation provides financial support for research being conducted on behalf of the OIFoundation, we do not specifically endorse any ongoing projects. We will, however, post research information on the BCF website as it is received from the OIFoundation.
As opportunities become available we will post them here:
The Brittle Bone Disorders Consortium (BBDC) is sponsoring a multicenter clinical trial to study the safety of fresolimumab treatment in adults with moderate-to-severe osteogenesis imperfecta (OI). This study will be conducted at two sites- Baylor College of Medicine in Houston, Texas and Oregon Health and Science University in Portland, Oregon. Research participants who meet the eligibility requirements will be asked to make 6 study visits over a 6-7 month timespan. Lodging and travel for the research participant and one travel companion is provided through the study.
Adults ages 18 years and older who have a diagnosis of moderate-to-severe OI and have no personal history of cancer or organ transplantation may be eligible to participate. Visit their Clinical Trials Website to learn more and determine your eligibility. Please use the information below to inquire about participation.
Baylor College of Medicine
Principal Investigators: Sandesh Nagamani, MD, Reid Sutton, MD, and Brendan Lee, MD, PhD
Contact: Dianne Dang
Address: Molecular and Human Genetics
1 Baylor Plaza, MS225
Houston, Texas 77030
Phone: (713) 798-6694
Oregon Health & Science University
Principal Investigator: Eric Orwoll, MD
Contact: Melanie Abrahamson, MPH, CCRP
Address: 3181 SW Sam Jackson Park Road, CR113
Portland, OR 97239
Phone: (503) 494-7480
Fax: (503) 494-6595
For more information, contact the Osteogenesis Imperfecta Foundation.
Disclaimer: The Bennett Clayton Foundation is not involved in the design or management of this research, and as such, is neither endorsing nor supporting this study. This information is made available as a service to the OI community.